Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Promega and SignalChem Pharmaceuticals have partnered to jointly introduce a kinase solution for the profiling of compounds against kinases representative of all major families of kinome.
Subscribe to our email newsletter
Promega and SignalChem Pharma said that the solution is a combination of an expanding series of Kinase Enzyme Systems and Promega’s new, bioluminescent ADP-Glo Kinase Assay, which is expected to provide all of the necessary tools and give drug screeners the ease to profile inhibitors against the human kinome for off-target effects.
Promega claimed that its ADP-Glo Kinase Assay is as sensitive as radiometric kinase assays and is used to optimise and QC the Kinase Enzyme Systems
Each Kinase System is made up of a protein kinase enzyme, cognate kinase substrate and enzyme buffer.
Jasbinder Sanghera, president and CSO of SignalChem Pharmaceuticals, said: “This partnering of SignalChem’s kinase reagents with the Promega ADP-Glo detection assay for kinases is an ideal fit. Now researchers can obtain all the necessary components to test protein kinase inhibition from a single source while still obtaining the level of sensitivity obtained with traditional radiometric assays.”